Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015;11(10):2337-44.
doi: 10.1080/21645515.2015.1066948.

Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years)

Fangjian Guo  1 , Jacqueline M Hirth  1 , Abbey B Berenson  1
Affiliations
Comparative Study

Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years)

Fangjian Guo et al. Hum Vaccin Immunother. 2015.

Abstract

There is some concern about the effectiveness of the HPV vaccine among young adult women due to the risk of prior HPV infection. This study used National Health and Nutrition Examination Survey (NHANES) 2007-2012 data to evaluate the effectiveness of HPV vaccination among women 20-26 years of age who were vaccinated after 12 years of age. This cross-sectional study examined 878 young adult women (20-26 years) with complete information on HPV prevalence and HPV vaccination status from NHANES 2007-2012. Vaginal swab specimens were analyzed for HPV DNA by L1 consensus polymerase chain reaction followed by type-specific hybridization. Multivariate logistic regression models controlling for sociodemographic characteristics and sexual behaviors were used to compare type-specific HPV prevalence between vaccinated and unvaccinated women. A total of 21.4% of young adult women surveyed through NHANES between 2007 and 2012 received the HPV vaccine. Vaccinated women had a lower prevalence of vaccine types than unvaccinated women (7.4% vs 17.1%, prevalence ratio 0.43, 95% CI 0.21-0.88). The prevalence of high-risk nonvaccine types was higher among vaccinated women than unvaccinated women (52.1% vs 40.4%, prevalence ratio 1.29, 95% CI 1.06-1.57), but this difference was attenuated after adjusting for sexual behavior variables (adjusted prevalence ratio 1.19, 95% CI 0.99-1.43). HPV vaccination was effective against all 4 vaccine types in young women vaccinated after age 12. However, vaccinated women had a higher prevalence of high-risk nonvaccine types, suggesting that they may benefit from newer vaccines covering additional types.

Keywords: HPV vaccine; high-risk type; human papillomavirus (HPV); oncogenic virus; prevalence.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prevalence of individual human papillomavirus (HPV) types among young adult women (20–26 years) by vaccination status. Prevalence was weighted using sample weights. * Statistical significance for the comparison between vaccinated women and unvaccinated women, after adjusted for age, race/ethnicity, education, income, smoking status, sexually transmitted infections, number of lifetime sexual partners, and number of sexual partners in the past 12 months.
See this image and copyright information in PMC

References

    1. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660-4; PMID:25299412; http://dx.doi.org/10.1097/OLQ.0000000000000193 - DOI - PMC - PubMed
    1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al.. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321-2; PMID:19350698; http://dx.doi.org/10.1016/S1470-2045(09)70096-8 - DOI - PubMed
    1. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al.. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8 - DOI - PubMed
    1. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al.. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-8; PMID:15863374; http://dx.doi.org/10.1016/S1470-2045(05)70101-7 - DOI - PubMed
    1. Group FIS . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741 - DOI - PubMed

Publication types

LinkOut - more resources